000136660 001__ 136660
000136660 005__ 20240229105053.0
000136660 0247_ $$2doi$$a10.1038/s41416-018-0152-4
000136660 0247_ $$2pmid$$apmid:29961759
000136660 0247_ $$2ISSN$$a0007-0920
000136660 0247_ $$2ISSN$$a1532-1827
000136660 0247_ $$2altmetric$$aaltmetric:46330183
000136660 037__ $$aDKFZ-2018-01129
000136660 041__ $$aeng
000136660 082__ $$a610
000136660 1001_ $$aBerger, Anne Katrin$$b0
000136660 245__ $$aEarly metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
000136660 260__ $$aEdinburgh$$bNature Publ. Group$$c2018
000136660 3367_ $$2DRIVER$$aarticle
000136660 3367_ $$2DataCite$$aOutput Types/Journal article
000136660 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536314014_14279
000136660 3367_ $$2BibTeX$$aARTICLE
000136660 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136660 3367_ $$00$$2EndNote$$aJournal Article
000136660 520__ $$aTo assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC).In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab. Primary endpoint was the predictive significance of ΔSUV for ECR. Secondary endpoints were PFS (progression free survival), OS and the influence of ΔSUV on survival.Forty pts were enroled and 33 pts were evaluable for the primary endpoint. The CT response rate was 57.6%. For responders, ΔSUV was significantly higher (p = 0.0092). A significant association of ΔSUV with ECR was found (p = 0.02). Median PFS was 11.7 months and median OS was 33.5 months with a 1-year survival rate of 87.9%. ΔSUV was found to significantly impact the hazard for OS (p = 0.045).We demonstrate that cetuximab induces metabolic responses in mCRC pts. The study endpoint was met with the ΔSUV discriminating between responders and non-responders. However, these data should be validated in larger patient cohorts.
000136660 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000136660 588__ $$aDataset connected to CrossRef, PubMed,
000136660 7001_ $$0P:(DE-He78)5bb4374f8998d504aa8d32fd671d5361$$aLücke, Stephan$$b1$$udkfz
000136660 7001_ $$0P:(DE-He78)a6cd39ee5b1d8276f6bc716b3f7881b7$$aAbel, Ulrich$$b2$$udkfz
000136660 7001_ $$aHaag, Georg Martin$$b3
000136660 7001_ $$aGrüllich, Carsten$$b4
000136660 7001_ $$aStange, Annika$$b5
000136660 7001_ $$aDietrich, Mareike$$b6
000136660 7001_ $$aApostolidis, Leonidas$$b7
000136660 7001_ $$0P:(DE-He78)18f02d73b8453009bc4fc3505c9432d7$$aFreitag, Angelika$$b8$$udkfz
000136660 7001_ $$0P:(DE-He78)f79f8d74000dfb47b912390d8a501f50$$aTrierweiler, Claudia$$b9$$udkfz
000136660 7001_ $$avon Gall, Carl$$b10
000136660 7001_ $$aOse, Jennifer$$b11
000136660 7001_ $$aGiesel, Frederik$$b12
000136660 7001_ $$aWeber, Tim Frederik$$b13
000136660 7001_ $$aLordick, Florian$$b14
000136660 7001_ $$aHaberkorn, Uwe$$b15
000136660 7001_ $$aJäger, Dirk$$b16
000136660 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-018-0152-4$$gVol. 119, no. 2, p. 170 - 175$$n2$$p170 - 175$$tBritish journal of cancer$$v119$$x1532-1827$$y2018
000136660 909CO $$ooai:inrepo02.dkfz.de:136660$$pVDB
000136660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5bb4374f8998d504aa8d32fd671d5361$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6cd39ee5b1d8276f6bc716b3f7881b7$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18f02d73b8453009bc4fc3505c9432d7$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136660 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f79f8d74000dfb47b912390d8a501f50$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000136660 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000136660 9141_ $$y2018
000136660 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2015
000136660 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136660 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136660 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136660 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136660 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136660 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136660 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136660 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136660 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136660 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136660 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136660 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136660 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2015
000136660 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x0
000136660 980__ $$ajournal
000136660 980__ $$aVDB
000136660 980__ $$aI:(DE-He78)G040-20160331
000136660 980__ $$aUNRESTRICTED